T he heart undergoes hypertrophy in response to pressure overload, a response generally considered to be an adaptive mechanism to reduce increased wall stress. When the stress is too great, or other molecular changes are elicited, hypertrophy can decompensate, leading to the development of heart failure. Macroautophagy (hereafter referred to as autophagy) has been implicated in this process. Autophagy is an intracellular system whereby cytoplasmic components and damaged organelles are sequestered in double-membrane vesicles called autophagosomes and delivered to lysosomes for degradation. Nutrient starvation or cellular stress rapidly induce autophagy, providing amino acids and fatty acids to synthesize proteins and to generate ATP, while also eliminating damaged mitochondria. [1] [2] [3] [4] Damaged mitochondria are the major source of reactive oxygen species contributing to apoptotic and necrotic cell death; thus, preservation of mitochondrial integrity is critical for cell survival. Mitochondrial quality control can be achieved through autophagy, mitochondria-selective autophagy (mitophagy), fission/fusion and mitochondrial biogenesis, processes that are in many ways interrelated. 5 There are, however, contradictory published observations regarding the timing or direction of changes in general autophagy, and its functional significance in the cardiac response to pressure overload remains controversial. [2] [3] [4] 6, 7 Moreover, whether the regulation of mitochondrial quality control by autophagy is beneficial or deleterious in the development of pressure overload-induced hypertrophy or its transition to heart failure has not been extensively studied.
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In this issue of Circulation, Shirakabe et al 8 provide greater clarity into the role of mitochondrial autophagy in pressure overload-induced cardiac hypertrophy and failure. By analyzing multiple time points from 1 hour to 30 days after transverse aortic constriction (TAC), the authors delineated sequential and ordered changes in autophagy and mitochondrial autophagy that occurred at different phases of development of TAC-induced hypertrophy and cardiac dysfunction ( Figure 1) . 8 General autophagy was rapidly increased between 1 and 12 hours after TAC, normalized at 1 to 3 days, and suppressed to below physiological levels from 5 days to 30 days after TAC. These changes in autophagy were evidenced by increased and decreased autophagic flux assessed by mRFP-GFP-LC3 puncta in the presence or absence of lysosome inhibition in vivo. The observation that autophagy is transiently activated, but normalized before and indeed suppressed in concert with the development of hypertrophy, suggests that autophagy is an early adaptive process that either signals, or is not integral to, regulation of hypertrophy and heart failure.
Shirakabe et al 8 further analyzed the process they specifically termed mitochondrial autophagy. Their studies included electron microscopic analysis of autophagosomes that contained mitochondria and also changes in mitochondrial DNA and mitochondrial matrix proteins. Interestingly, mitochondrial autophagy was found to be activated at the same time that general autophagy was normalized (it increased at 3 days after TAC) and also to be transient, normalizing at 1 week after TAC ( Figure 1 ). 8 Additional studies used AAV9-mediated coexpression of Mito-Keima and YFP-Lamp1 in the heart to demonstrate increased delivery of mitochondria to the lysosomal compartment at 3 to 7 days after TAC. The population of foreshortened mitochondria was concomitantly increased. Importantly, the decline of mitochondrial autophagy directly preceded development of mitochondrial dysfunction.
Drp1, a mitochondrial fission protein, was genetically deleted in the adult heart by this same laboratory and the cardiac-specific conditional Drp1 knockout was shown to develop ventricular dysfunction and lethality. 9 The time course of phosphorylation and mitochondrial translocation of Drp1 examined in the current study was found to peak at 3 days after TAC, thus to be temporally associated with the development of mitochondrial autophagy. To directly assess involvement of Drp1 in the sequence of events described above, cardiac-specific heterozygous Drp1 knockout mice were subject to TAC. Mitochondrial autophagy was suppressed and the increase in the population of the foreshortened mitochondria was largely attenuated. Remarkably, decreasing endogenous Drp1 also led to a more rapid onset of mitochondrial dysfunction and accelerated TAC-induced cardiac hypertrophy and dysfunction. These results strongly suggest that Drp1 regulates the size of mitochondria and mitochondrial autophagy in the heart subjected to TAC and that mitochondrial autophagy serves as a compensatory and adaptive response to maintain mitochondrial quality in the face of pressure overload.
To further determine whether increasing autophagy could rescue the heart from TAC-induced heart failure, the authors used a TAT-Beclin 1 peptide that liberates endogenous Beclin 1 from the Golgi apparatus and thereby
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increases Beclin1 available to regulate of autophagy. 10 TATBeclin 1 peptide was administered on day 7, a time at which autophagy was suppressed and mitochondrial autophagy was declining, and shown to restore these responses at 30 days. Strikingly, this also lead to improved mitochondrial function and prevented the development of heart failure, as evidenced by decreased myocyte size, inhibition of lung edema, preserved contractile function, and diminished cardiomyocyte cell death. Importantly, TAT-Beclin 1 peptide could not overcome the deleterious effects of haploinsufficiency of Drp1. Thus, Drp1 is required for the protective effect of Beclin 1, supporting the concept that Drp1 plays a crucial role in compensatory autophagic clearance of mitochondria and mitochondrial quality control.
A question that is not conclusively answered in this study is what molecular mechanisms are responsible for the induction of mitochondrial autophagy by pressure overload. Is this process the same as the previously described mitochondriaselective autophagy (mitophagy), as depicted in Figure 2 ? It is notable that 2 major events in mitophagy, Parkin translocation to mitochondria and ubiquitination of mitochondrial proteins, were examined and found not to occur at the time that mitochondrial autophagy was increased. Accordingly, the established process of Parkin-mediated mitophagy does not appear to be responsible for the mitochondrial autophagy observed following TAC. In addition, TAC-induced mitochondrial autophagy did not begin until general autophagy had returned to basal levels; thus, general autophagy of mitochondria seems unlikely to assume this function. Shirakabe et al 8 speculate that an alternative form of autophagy, which is Atg5-or Atg7-independent and cannot be evaluated by conventional markers such as LC3-II, 11 plays a role in mitochondrial autophagy regulated by Drp1 in response to pressure overload. The occurrence of alternative autophagy in the heart has not been well documented; thus, further study will be required to test this intriguing possibility. More detailed mechanistic information will be needed to dissect and determine the role of general autophagy, alternative autophagy, mitophagy, and their contributions to mitochondrial quality control (Figure 2) .
Shirakabe et al 8 demonstrate that at day 2 following TAC there is increased phosphorylation of Drp1 at Ser616 and concomitantly decreased phosphorylation at Ser637. Published work has identified Cdk1, PKCδ, and ERK as kinases that mediate phosphorylation of Drp1 at Ser616 and increase its translocation to mitochondria 12 ; PKA, CaMKIα, Pim-1, and ROCK1 have been reported to phosphorylate Drp1 at Ser637, inhibiting Drp1 translocation to mitochondria in some but not all studies. 12, 13 Interestingly, Ser637 is also a target for calcineurin-dependent dephosphorylation. 12 In addition to phosphorylation, Drp1 undergoes multiple posttranscriptional modifications including S-nitrosylation, sumoylation, and O-GlcNAcylation. 12 There has been extensive research into the signaling pathways by which pressure 
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Mitochondrial Autophagy in Heart Failure 1227 overload leads to cardiac hypertrophy and heart failure. Similar delineation of the signals transducing pressure overload to Drp1 mitochondrial translocation may be the next frontier in understanding how mitochondrial quality control is regulated and its cessation contributes to the progression and decompensation of cardiac hypertrophy. Drp1 plays an active role in mitochondrial fission, suggested to be a prerequisite step for mitochondrial autophagy. 12,14 Whether Drp1-dependent fission is mechanistically linked to Drp1-induced mitochondrial autophagy remains to be determined. A dynamic interdependence between fission and mitochondrial autophagy could underlie the disparate time-dependent effects of complete Drp1 deletion in the adult heart observed in different laboratories. 9, [14] [15] [16] Finally, it is of considerable interest that general autophagy is such an early and transient response, and that mitochondrial autophagy is also self-limited, turning off after the first week of pressure overload. In light of the evidence that mitochondrial autophagy seems to prevent development of mitochondrial dysfunction and heart failure, understanding why the process is halted could provide important insights into how to prevent this progression. A decline in mitochondrial quality control is increasingly appreciated as a major factor in the development of hypertrophy and heart failure. Accordingly, mitochondrial autophagy can be viewed as a means of protecting the heart against the toxic effects of reactive oxygen species production by dysfunctional mitochondria. 4, 5, 9, 14, [17] [18] [19] [20] The work by Shirakabe et al 8 provides new insights into the role of Drp1-mediated mitochondrial autophagy, suggesting that this is part of a compensatory pathway that serves to protect the heart against pressure overload-induced maladaptive hypertrophy and limit cardiac decompensation.
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